Artificial Intelligence in Oncology: A 10-Year ClinicalTrials.gov-Based Analysis Across the Cancer Control Continuum.

ABSTRACT:

Background/objectives

Artificial Intelligence (AI) is rapidly advancing in medicine, facilitating personalized care by leveraging complex clinical data, imaging, and patient monitoring. This study characterizes current practices in AI use within oncology clinical trials by analyzing completed U.S. trials within the Cancer Control Continuum (CCC), a framework that spans the stages of cancer etiology, prevention, detection, diagnosis, treatment, and survivorship.

Methods

This cross-sectional study analyzed U.S.-based oncology trials registered on ClinicalTrials.gov between January 2015 and April 2025. Using AI-related MeSH terms, we identified trials addressing stages of the CCC.

Results

Fifty completed oncology trials involving AI were identified; 66% were intervention

SUBMITTER: Verma H 

PROVIDER: S-EPMC12607805 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature